Innovent Biologics Dirección

Dirección controles de criterios 2/4

El CEO de Innovent Biologics es Michael Yu , nombrado en Jan 2011, tiene una permanencia de 13.92 años. compensación anual total es CN¥36.44M, compuesta por 7.9% salario y 92.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 6.53% de las acciones de la empresa, por valor de $484.40M. La antigüedad media del equipo directivo y de la junta directiva es de 0.9 años y 3.3 años, respectivamente.

Información clave

Michael Yu

Chief Executive Officer (CEO)

CN¥36.4m

Compensación total

Porcentaje del salario del CEO	7.9%
Permanencia del CEO	13.9yrs
Participación del CEO	6.5%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Michael Yu en comparación con los beneficios de Innovent Biologics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥1b
Dec 31 2023	CN¥36m	CN¥3m	-CN¥1b
Sep 30 2023	n/a	n/a	-CN¥1b
Jun 30 2023	n/a	n/a	-CN¥1b
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥33m	CN¥3m	-CN¥2b
Sep 30 2022	n/a	n/a	-CN¥2b
Jun 30 2022	n/a	n/a	-CN¥3b
Mar 31 2022	n/a	n/a	-CN¥3b
Dec 31 2021	CN¥26m	CN¥3m	-CN¥3b
Sep 30 2021	n/a	n/a	-CN¥2b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥1b
Dec 31 2020	CN¥105m	CN¥3m	-CN¥998m
Sep 30 2020	n/a	n/a	-CN¥1b
Jun 30 2020	n/a	n/a	-CN¥2b
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥76m	CN¥3m	-CN¥2b

Compensación vs. Mercado: La compensación total de Michael($USD5.00M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD8.00M).

Compensación vs. Ingresos: La compensación de Michael ha aumentado mientras la empresa no es rentable.

CEO

Michael Yu (60 yo)

13.9yrs

Permanencia

CN¥36,444,000

Compensación

Dr. De-Chao Yu, also known as Michael, Ph.D. Co-Founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Biol...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
De-Chao Yu	Co-Founder	13.9yrs	CN¥36.44m	6.53% $ 484.4m
Hao Xi Ede	Executive Director & Fund Managing Partner	less than a year	CN¥7.10m	0.20% $ 14.7m
Fei You	Chief Financial Officer	less than a year	sin datos	sin datos
Vivian Zhang	Chief People Officer	5.4yrs	sin datos	0.020% $ 1.5m
Min Liu	Chief Commercial Officer	no data	sin datos	sin datos
Dongming Wang	Senior Vice President	4.9yrs	sin datos	sin datos
Blake Salisbury	Senior Vice President	no data	sin datos	sin datos
Hui Zhou	Senior Vice President	less than a year	sin datos	sin datos
Nageatte Ibrahim	Oncology Chief Medical Officer	less than a year	sin datos	sin datos
Samuel Suhua Zhang	Global Chief Business Officer	less than a year	sin datos	sin datos
Raj Dhodda	Senior Vice President	less than a year	sin datos	sin datos
Yanju Wang	Joint Company Secretary	6.5yrs	sin datos	sin datos

0.9yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IVBX.F no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
De-Chao Yu	Co-Founder	13.9yrs	CN¥36.44m	6.53% $ 484.4m
Hao Xi Ede	Executive Director & Fund Managing Partner	no data	CN¥7.10m	0.20% $ 14.7m
Vivian Zhang	Chief People Officer	less than a year	sin datos	0.020% $ 1.5m
Charles Leland Cooney	Member of CMC Strategic Advisory Board & Independent Non-Executive Director	9.2yrs	CN¥400.00k	0.0028% $ 205.4k
Lewis Lanier	Member of Scientific Advisory Board	3.3yrs	sin datos	sin datos
I-Yin Hsu	Independent Non-Executive Director	6.2yrs	CN¥400.00k	0.00039% $ 28.9k
Erwin Vanhaecke	Member of CMC Strategic Advisory Board	no data	sin datos	sin datos
Kai-Xian Chen	Independent Non-Executive Director	6.2yrs	CN¥400.00k	0.00033% $ 24.5k
David LaPre	Member of CMC Strategic Advisory Board	no data	sin datos	sin datos
Shuyun Chen	Independent Non-Executive Director	less than a year	sin datos	0.00067% $ 49.7k
Lawrence Fong	Member of Scientific Advisory Board	3.3yrs	sin datos	sin datos
Carlos Garcia-Echeverria	Member of Scientific Advisory Board	3.3yrs	sin datos	sin datos

3.3yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de IVBX.F se considera experimentada (3.3 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2024/12/22 05:14
Precio de las acciones al final del día	2024/12/20 00:00
Beneficios	2024/06/30
Ingresos anuales	2023/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .

Fuentes analistas

Innovent Biologics, Inc. está cubierta por 53 analistas. 29 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Linda Lu	BOCI Research Ltd.
Wai Chak Yuen	BOCI Research Ltd.
Bo Li	BofA Global Research

Innovent Biologics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Appoints Gary Zieziula as Independent Non-Executive Director

Recent updates

Innovent Biologics, Inc. Receives Approval of DOVBLERON®? (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Presents Updated Data from Innovative Anti-CLDN18.2 Adc (Ibi343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the Esmo Asia Congress 2024

Innovent Biologics, Inc. Announces First-Time Inclusion of SINTBILO and New Indication for Olverembatinib in China's National Reimbursement Drug List

Innovent Biologics, Inc. Announces Acceptance of New Drug Application for Picankibart Injection by China's NMPA

Innovent Biologics, Inc. Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress

Innovent Biologics, Inc. Announces Change in Composition of Board Committees

Innovent Biologics, Inc. Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China

The National Medical Products Administration Approves Centre for Drug Evaluation of the National Medical Products Administration of China's First KRAS G12C Inhibitor Dupert

Innovent Biologics, Inc. to Report First Half, 2024 Results on Aug 28, 2024

Innovent Biologics, Inc. and Sanegene Bio USA Inc. Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)

the National Medical Products Administration of China Accepts the New Drug Application of Mazdutide of Innovent Biologics, Inc

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib

Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity

Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma

Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study

Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)

Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint

Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema

Innovent Biologics, Inc. announced that it expects to receive HKD 4.83336 billion in funding from Sanofi Foreign Participations B.V.

Innovent Biologics, Inc. and Laekna Jointly Announce First Patient Dosed with Three-Drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy

Innovent Biologics, Inc. Announces CDE Accepts and Grants Priority Review Designation to New Drug Application